15198-07-9

Basic information

• Product Name: 2-hydroxy-3-methylbenzoyl chloride
• Synonyms: 2-hydroxy-3-methylbenzoyl chloride;2-Hydroxy-3-methylbenzoic acid chloride;Einecs 239-253-9
• CAS NO: 15198-07-9
• Molecular Formula: C₈H₇ClO₂
• Molecular Weight: 170.59298
• EINECS: 239-253-9
• Mol File: 15198-07-9.mol

Chemical Properties

• Boiling Point: 273.6°Cat760mmHg
• Flash Point: 119.3°C
• Appearance: /
• Density: 1.306g/cm³
• Vapor Pressure: 0.0034mmHg at 25°C
• Refractive Index: 1.576
• CAS DataBase Reference: 2-hydroxy-3-methylbenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-hydroxy-3-methylbenzoyl chloride(15198-07-9)
• EPA Substance Registry System: 2-hydroxy-3-methylbenzoyl chloride(15198-07-9)

Safety Data

• Hazardous Substances Data: 15198-07-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H7ClO2/c1-5-3-2-4-6(7(5)10)8(9)11/h2-4,10H,1H3

Upstream product

• 83-40-9 3-methylsalicylic acid 
• 7719-09-7 thionyl chloride 
• 10026-13-8 phosphorus pentachloride 

Downstream Products

• 55211-85-3 ethyl 2-hydroxy-3-methylbenzoate 
• 43096-27-1 N-(9,10-Dioxo-4-p-tolylamino-9,10-dihydro-anthracen-1-yl)-2-hydroxy-3-methyl-benzamide 
• 6279-04-5 4'-chloro-2-hydroxy-3-methyl-benzophenone 
• 56048-53-4 2-(2'-hydroxy-3'-methylphenyl)benzothiazole 
• 100912-07-0 2-Cyclohexylmethyl-6-methyl-cyclohexanol 
• 1697-21-8 8-methyl-2-phenyl-3-p-tolyl-2,3-dihydro-benzo[e][1,3]oxazin-4-one 
• 1834-56-6 3-(2,4-dimethyl-phenyl)-8-methyl-2-phenyl-2,3-dihydro-benzo[e][1,3]oxazin-4-one 
• 1697-20-7 8-methyl-2,3-diphenyl-2,3-dihydro-benzo[e][1,3]oxazin-4-one 
• 824-42-0 2-methoxy-3-methylbenzaldehyde 
• 1697-22-9 3-(2,5-dimethyl-phenyl)-8-methyl-2-phenyl-2,3-dihydro-benzo[e][1,3]oxazin-4-one 
• 1697-23-0 3-(3,4-dimethyl-phenyl)-8-methyl-2-phenyl-2,3-dihydro-benzo[e][1,3]oxazin-4-one 
• 1697-24-1 3-(3-chloro-phenyl)-8-methyl-2-phenyl-2,3-dihydro-benzo[e][1,3]oxazin-4-one 
• 4072-08-6 (2-hydroxy-3-methylphenyl)(phenyl)methanone 
• 111849-53-7 2-hydroxy-3-methyl-benzoic acid-[2]naphthylamide 

Relevant articles and documents

Discovery of potent inhibitors of Schistosoma mansoni NAD+ catabolizing enzyme

The blood fluke Schistosoma mansoni is the causative agent of the intestinal form of schistosomiasis (or bilharzia). Emergence of Schistosoma mansoni with reduced sensitivity to praziquantel, the drug currently used to treat this neglected disease, has underlined the need for development of new strategies to control schistosomiasis. Our ability to screen drug libraries for antischistosomal compounds has been hampered by the lack of validated S. mansoni targets. In the present work, we describe a virtual screening approach to identify inhibitors of S. mansoni NAD+ catabolizing enzyme (SmNACE), a receptor enzyme suspected to be involved in immune evasion by the parasite at the adult stage. Docking of commercial libraries into a homology model of the enzyme has led to the discovery of two in vitro micromolar inhibitors. Further structure-activity relationship studies have allowed a 3-log gain in potency, accompanied by a largely enhanced selectivity for the parasitic enzyme over the human homologue CD38.

Design, synthesis, and biological evaluation of 3′,4′,5′-trimethoxy evodiamine derivatives as potential antitumor agents

A series of compounds bearing 3′,4′,5′-trimethoxy module into the core structure of evodiamine were designed and synthesized. The synthesized compounds were screened in vitro for their antitumor potential. MTT results showed that compounds 14a–14c and 14i–14j had significant effects, with compound 14h being the most prominent, with an IC50 value of 3.3 ± 1.5?μM, which was lower than evodiamine and 5-Fu. Subsequent experiments further confirmed that compound 14h could inhibit cell proliferation and migration, and induce G2/M phase arrest to inhibit the proliferation of HGC-27 cells, which is consistent with the results of the cytotoxicity experiment. Besides, 14h could inhibit microtubule assembly and might kill tumor cells by inhibiting VEGF and glycolysis. All experimental results indicate that compound 14h might be a potential drug candidate for the treatment of gastric cancer and was worthy of further study.

Structure-Activity Study of Nitazoxanide Derivatives as Novel STAT3 Pathway Inhibitors

We identified nitazoxanide (NTZ) as a moderate STAT3 pathway inhibitor through immunoblot analysis and a cell-based IL-6/JAK/STAT3 pathway activation assay. A series of thiazolide derivatives were designed and synthesized to further validate the thiazolide scaffold as STAT3 inhibitors. Eight out of 25 derivatives displayed potencies greater than that of NTZ, and their STAT3 pathway inhibitory activities were found to be significantly correlated with their antiproliferative activities in HeLa cells. Derivatives 15 and 24 were observed to be more potent than the positive control WP1066, which is under phase I clinical trials. Compared with NTZ, 15 also exhibited much improved in vivo pharmacokinetic parameters in rats and efficacies against proliferations in multiple cancer cell lines, indicating a broad-spectrum effect of these thiazolides as antitumor agents targeted on STAT3.

Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer

Evodiamine (Evo) is a quinazolinocarboline alkaloid found in Evodia rutaecarpa and exhibits moderate antiproliferative activity. Herein, we report using a scaffold-hopping approach to identify a series of novel polycyclic heterocyclic derivatives based on Evo as the topoisomerase I (Top1) inhibitor for the treatment of triple-negative breast cancer (TNBC), which is an aggressive subtype of breast cancer with limited treatment options. The most potent compound 7f inhibited cell growth in a human breast carcinoma cell line (MDA-MB-231) with an IC50 value of 0.36 μM. Further studies revealed that Top1 was the target of 7f, which directly induced irreversible Top1-DNA covalent complex formation or induced an oxidative DNA lesion through an indirect mechanism mediated by reactive oxygen species. More importantly, in vivo studies showed that 7f exhibited potent antitumor activity in a TNBC-patient-derived tumor xenograft model. These results suggest that compound 7f deserves further investigation as a promising candidate for the treatment of TNBC.

SAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway

Disruption of cyclic adenosine monophosphate response element binding protein (CREB) provides a potential new strategy to address acute leukemia, a disease associated with poor prognosis, and for which conventional treatment options often carry a significant risk of morbidity and mortality. We describe the structure-activity relationships (SAR) for a series of XX-650-23 derived from naphthol AS-E phosphate that disrupts binding and activation of CREB by the CREB-binding protein (CBP). Through the development of this series, we identified several salicylamides that are potent inhibitors of acute leukemia cell viability through inhibition of CREB-CBP interaction. Among them, a biphenyl salicylamide, compound 71, was identified as a potent inhibitor of CREB-CBP interaction with improved physicochemical properties relative to previously described derivatives of naphthol AS-E phosphate.

Bifunctional fluorescent probe for detecting viscosity and sulfur dioxide

The invention discloses a bifunctional fluorescent probe for detecting viscosity and sulfur dioxide. The red fluorescence of the fluorescent probe is gradually enhanced along with the increase of viscosity, and the blue fluorescence of the fluorescent probe is enhanced along with the increase of SO2, so that different fluorescence response signals are displayed, and the distinguishing detection isrealized. The fluorescent probe provided by the invention has important application value in the field of biochemistry.

Synthesis, pharmacophore modeling and in vitro activity of 10,11-dihydrodibenzo[b,f]oxepine-4-carboxamide derivatives as novel and potent antagonists of the prostaglandin EP4 receptor

The construction of a EP4 antagonists pharmacophore model and the discovery of a highly potent oxepinic series of EP4 antagonists is discussed. Compound 1a exhibits an excellent selectivity profile toward EP2 receptor subtype and low cytochrome P450 inhibition potential.

Syntheses and Properties of Selenium-bridged Bischromones

The preparation of the new selenium-bridged chromones 5a-e is described.Compound 5c reacts with m-CPBA under various conditions to give the corresponding selenoxide 7 and the Pummerer products 8 and 9.The selenides 5a-c react with excess m-CPBA to form the diselenides 13a-c.Oxidation of 13c with hydrogen peroxide afforded the chromone-3-seleninic acid 22.

Antianaphylactic Benzophenones and Related Compounds

The synthesis and biological properties of 85 benzophenones and related compounds are described.The majority of the compounds inhibit the release of leukotrienes (LT) C4 and D4 in vitro from sensitized guinea pig chopped lung.In addition, some of the compounds inhibited the release of LTs from passively sensitized human chopped lung and protected guinea pigs from the effects of anaphylaxis in a modified Herxheimer test.